OPKO Health (NASDAQ:OPK) Issues Quarterly Earnings Results, Beats Estimates By $0.07 EPS

OPKO Health (NASDAQ:OPK) posted its quarterly earnings results on Monday. The biotechnology company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.07, FiscalAI reports. OPKO Health had a negative return on equity of 5.79% and a negative net margin of 12.40%.The firm had revenue of $163.58 million during the quarter, compared to analysts’ expectations of $131.23 million. During the same quarter in the prior year, the firm posted ($0.19) EPS. The company’s revenue for the quarter was up 4.3% on a year-over-year basis.

Here are the key takeaways from OPKO Health’s conference call:

• OPKO significantly improved profitability in Q2, with consolidated revenue rising to $163.6 million, operating loss narrowing to $7 million from $60 million, and net loss improving to $8.4 million from $148.4 million.
• Management raised full-year 2026 revenue guidance to $560 million-$585 million and reduced total cost and expense guidance to $710 million-$740 million, while maintaining its expectation that BioReference will reach breakeven or operating profitability this year.
• The pipeline continues to advance, including five ModeX programs in clinical development, an expected first-in-human trial for the in vivo CAR-T program by late 2026 or early 2027, and the initiation of a Phase I/IIa trial for the GLP-1/glucagon candidate OPKO-88006 in MASH.
• OPKO ended the quarter with more than $300 million in cash and restricted cash and repurchased 9.7 million shares for approximately $13 million, with another $94 million authorized for buybacks.
• BioReference’s 4Kscore growth and broader primary-care expansion remain dependent on Medicare reimbursement changes that have not yet been approved, with management now expecting the larger opportunity to contribute mainly from 2027 onward; full-year services guidance was also reduced slightly.

OPKO Health Price Performance

Shares of OPK stock opened at $1.65 on Wednesday. The stock’s fifty day simple moving average is $1.38 and its 200 day simple moving average is $1.27. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.61 and a quick ratio of 3.17. The firm has a market cap of $1.25 billion, a price-to-earnings ratio of -18.33 and a beta of 1.48. OPKO Health has a one year low of $0.98 and a one year high of $1.73.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. Weiss Ratings raised OPKO Health from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, May 18th. HC Wainwright restated a “buy” rating on shares of OPKO Health in a research note on Wednesday. Wall Street Zen raised OPKO Health from a “sell” rating to a “hold” rating in a research report on Saturday, June 6th. Finally, Barrington Research downgraded shares of OPKO Health from an “outperform” rating to a “market perform” rating in a research note on Wednesday, April 29th. One analyst has rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, OPKO Health has a consensus rating of “Hold” and a consensus price target of $1.55.

Institutional Investors Weigh In On OPKO Health

Institutional investors and hedge funds have recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of OPKO Health by 4.7% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 198,148 shares of the biotechnology company’s stock worth $262,000 after purchasing an additional 8,954 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in OPKO Health by 11.2% in the second quarter. The Manufacturers Life Insurance Company now owns 138,643 shares of the biotechnology company’s stock valued at $183,000 after buying an additional 13,912 shares in the last quarter. Intech Investment Management LLC boosted its position in OPKO Health by 11.4% in the fourth quarter. Intech Investment Management LLC now owns 159,652 shares of the biotechnology company’s stock valued at $201,000 after buying an additional 16,329 shares in the last quarter. Prudential Financial Inc. grew its stake in OPKO Health by 75.0% during the second quarter. Prudential Financial Inc. now owns 46,842 shares of the biotechnology company’s stock worth $62,000 after buying an additional 20,076 shares during the last quarter. Finally, Graham Capital Management L.P. grew its stake in OPKO Health by 21.6% during the fourth quarter. Graham Capital Management L.P. now owns 119,654 shares of the biotechnology company’s stock worth $151,000 after buying an additional 21,286 shares during the last quarter. Institutional investors and hedge funds own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.